These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9689885)

  • 1. [Bone-specific treatment design in the treatment of postmenopausal osteoporosis. Pharmaco-economic aspects].
    Reginster JY; Ben Sedrine W; Gosset C
    Rev Med Liege; 1998 May; 53(5):290-3. PubMed ID: 9689885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions.
    Tosteson AN; Jönsson B; Grima DT; O'Brien BJ; Black DM; Adachi JD
    Osteoporos Int; 2001; 12(10):849-57. PubMed ID: 11716188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation.
    Ray NF; Chan JK; Thamer M; Melton LJ
    J Bone Miner Res; 1997 Jan; 12(1):24-35. PubMed ID: 9240722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Osteoporosis in health economic perspective].
    Borgström F
    Lakartidningen; 2006 Oct 4-10; 103(40):2963-5. PubMed ID: 17115658
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prevention of osteoporosis and its economic aspects].
    Blachier C
    Cah Sociol Demogr Med; 1999; 39(2-3):271-82. PubMed ID: 10615567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy.
    Xenodemetropoulos T; Davison S; Ioannidis G; Adachi JD
    Drugs Aging; 2004; 21(11):711-30. PubMed ID: 15323577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients.
    Hiligsmann M; Rabenda V; Bruyère O; Reginster JY
    Health Policy; 2010 Jul; 96(2):170-7. PubMed ID: 20153543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of osteoporosis prevention.
    Johannesson M; Jönsson B
    Health Policy; 1993 May; 24(2):103-24. PubMed ID: 10126753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis.
    Mueller D; Gandjour A
    Appl Health Econ Health Policy; 2011 Jul; 9(4):259-73. PubMed ID: 21682353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis.
    Dere W; Avouac B; Boers M; Buxton M; Christiansen C; Dawson A; Gennari C; Guillemin F; Lawaetz H; Ornskov F; Roumagnac I; Reginster JY
    Calcif Tissue Int; 1998 Aug; 63(2):93-7. PubMed ID: 9685510
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].
    Jönsson L; Borgström F; Zethraeus N
    Ugeskr Laeger; 2003 Oct; 165(43):4112-6. PubMed ID: 14619061
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
    Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women.
    Josse RG
    CMAJ; 1996 Oct; 155(7):929-34. PubMed ID: 8837542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.
    Borgström F; Ström O; Marin F; Kutahov A; Ljunggren O
    J Med Econ; 2010; 13(3):381-92. PubMed ID: 20604678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morbidity of osteoporosis--can estrogen use make a public health impact?
    Hartmann DM
    Curr Opin Obstet Gynecol; 1997 Oct; 9(5):289-94. PubMed ID: 9360808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic analysis of strategies to treat postmenopausal osteoporosis: a systematic review.
    Brandão CM; Machado GP; Acurcio Fde A
    Rev Bras Reumatol; 2012 Dec; 52(6):924-37. PubMed ID: 23223702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.
    Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ
    Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis and the burden of osteoporosis-related fractures.
    Dempster DW
    Am J Manag Care; 2011 May; 17 Suppl 6():S164-9. PubMed ID: 21761955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The societal burden of osteoporosis in Sweden.
    Borgström F; Sobocki P; Ström O; Jönsson B
    Bone; 2007 Jun; 40(6):1602-9. PubMed ID: 17433804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.